Search
On this page:
Powering results across mRNA bioprocessing workflows
As mRNA programs move toward commercial manufacturing, risk can increase when process steps are developed in isolation. Yield, scalability, and cost are influenced by how plasmid DNA (pDNA) production, messenger RNA (mRNA) synthesis, purification, analytics, and fill–finish work together. Thermo Fisher Scientific supports mRNA manufacturing with bioprocessing solutions across these steps, helping teams reduce variability, improve predictability, and make informed decisions as processes mature.
Plasmid DNA production for mRNA workflows
Plasmid DNA production forms a defined upstream workflow that directly influences mRNA yield, quality attributes, and scalability. Structuring plasmid DNA production as an integrated, four-step process helps maintain consistency from early development through commercial manufacturing.
Establish controlled microbial fermentation to drive plasmid replication with consistency across increasing operating volumes and development stages. Optimize culture conditions and induction strategies to support plasmid yield and quality while maintaining flexibility from development through commercial manufacturing. Glass and single-use fermentors, paired with configurable bioprocess controllers and integrated automation software, help maintain reproducible control of key parameters.
Process biomass efficiently to release plasmid DNA while maintaining containment and consistency. Apply alkaline lysis strategies to disrupt E. coli cells, then separate the cell debris using centrifugation systems. Single-use mixers and closed bioprocess containers (BPCs) support controlled lysis, neutralization, and intermediate handling while reducing open manipulations.
Reduce impurities and condition plasmid DNA to optimize downstream mRNA production. Perform buffer exchange to minimize salts and process-related contaminants, then apply chromatographic purification to separate plasmid DNA from host-derived impurities. Single-use chromatography platforms, supported by scalable mixers and buffer management solutions, help maintain control at larger process volumes. Anion exchange (AEX) chromatography resins enable high-capacity plasmid capture. Hydrophobic interaction chromatography (HIC) resins and mixed-mode chromatography (MMC) resin support impurity reduction through complementary separation mechanisms.
Confirm plasmid DNA quality and readiness for mRNA manufacturing through targeted analytical testing. Apply automated sample preparation and qPCR-based residual host DNA assays to assess clearance of host-derived impurities. Complement molecular assays with microbial testing approaches to monitor contamination risks.
Scalable mRNA synthesis and purification
Transition from plasmid DNA to mRNA drug substance through a structured, multi-step downstream workflow. Treating these activities as a connected sequence helps teams maintain process consistency, align upstream decisions with downstream performance, and prepare mRNA workflows for reliable execution.
Convert plasmid DNA into mRNA through controlled enzymatic transcription under defined process conditions. Use glass and single-use bioreactors or controlled reaction vessels to support scalable in vitro transcription (IVT) while maintaining temperature control, mixing, and reaction consistency. Configurable bioprocess controllers and integrated automation software help align process parameters across development and manufacturing.
Isolate and condition mRNA to support downstream formulation and fill–finish readiness by applying an impurity control strategy that begins upstream. Designing a clean IVT reaction helps limit process- and reaction-related impurities early. This enables affinity-based capture to selectively recover full-length mRNA and reduces many impurities in a single step.
Affinity chromatography resins, including Thermo Scientific POROS Oligo (dT)25 Affinity Resin, support selective mRNA capture through poly(A) interactions. Where more refinement is needed, intermediate polishing steps can be introduced to manage residual impurities. These approaches may include ion exchange (IEX) chromatography, HIC, and MMC, which offer complementary separation mechanisms to meet process needs and scalability.
Verify mRNA quality and process readiness before encapsulation. Apply targeted assays to assess residual DNA, reaction-related impurities, and bioburden while preserving limited sample volumes. The Applied Biosystems resDNASEQ Quantitative Plasmid DNA - Kanamycin Resistance Gene Kits enable confirmation of template clearance. Microbial identification helps monitor contamination risks during downstream operations.
Transition mRNA drug substance into drug product under controlled processing conditions. Support formulation and encapsulation using single-use mixers. Single-use mixers are designed to support mRNA handling and lipid-based systems at production-relevant volumes for the intended scale, under controlled mixing conditions. Bioprocess containers and flexible containment solutions help manage in-process holding and transfers with closed handling approaches. Fill–finish solutions can support final filling, sealing, and handling activities aligned with cGMP requirements, helping teams maintain predictable performance as mRNA workflows advance.
Process liquid preparation, transfer, and containment
Process liquids underpin multiple stages of mRNA bioprocessing, from fermentation and lysis through purification, formulation, and fill–finish. Organizing process liquid activities into a defined, step-based workflow helps teams maintain consistency, align upstream and downstream operations, and support predictable execution.
Prepare buffers, media, and reagents as the foundation for consistent mRNA bioprocessing. Start with controlled hydration of dry powder media (DPM) or use ready-to-use process liquids to support fermentation, lysis, purification, and formulation steps. Standardized preparation approaches help reduce variability introduced during weighing, mixing, and dilution while enabling reproducibility across development and manufacturing volumes. Aligning buffer and media preparation early in process development establishes a stable starting point.
Support active unit operations by mixing and holding process liquids under controlled conditions throughout the mRNA workflow. Use scalable mixing platforms to prepare, condition, and maintain buffers during lysis, purification, and formulation while accommodating changing volume requirements. Flexible mixing and short-term holding strategies preserve homogeneity, support temperature-sensitive materials, and allow operational flexibility as processes evolve.
Move process liquids between unit operations using closed handling approaches to maintain control and reduce variability. Design transfer pathways that support upstream, downstream, and fill–finish activities while aligning with facility layouts and process requirements. Closed systems protect material integrity, minimize open manipulations, and allow reliable execution as workflows progress toward manufacturing.
Protect process liquids and intermediates during short- and long-term storage across the mRNA manufacturing workflow. Select storage and containment solutions that enable material integrity, documentation requirements, and handling needs in development and cGMP environments. Bioprocess bottles and carboys, along with flexible and rigid containment options, support staging, transport, and storage as materials move between upstream, downstream, and fill–finish operations.
Related resources
Frequently asked questions
Integrated mRNA bioprocessing workflows can reduce scale-up risk by improving visibility into how upstream and downstream decisions affect performance as volumes increase. Coordinating unit operations, analytics, and process liquids helps teams identify sources of variability earlier and address them before technology transfer.
Plasmid DNA processes should be designed with downstream purification and overall mRNA workflow requirements in mind, while recognizing that IVT is a core upstream step. Fermentation conditions, lysis methods, and purification strategies influence plasmid quality attributes that affect transcription performance and downstream impurity profiles. Selecting scalable platforms and closed handling approaches early helps simplify scale-up and reduce late-stage process changes.
Purification strategies determine both mRNA recovery and impurity clearance. Capture methods influence selectivity for full-length mRNA, while polishing steps affect the reduction of residual DNA, enzymes, and reaction byproducts. Balancing capture efficiency with impurity reduction helps minimize reprocessing, enabling consistent product quality at larger manufacturing volumes.
Process development teams can prepare early by selecting platforms, process liquids, and analytical methods that are transferable across scales. Designing workflows with closed handling, consistent equipment formats, and clear documentation reduces rework during technology transfer and supports smoother progression into manufacturing.
Standardized process liquids and fluid handling approaches reduce variability introduced during preparation, transfer, and storage. Using qualified buffers, ready-to-use liquids, and closed transfer systems supports consistent execution across unit operations and simplifies process control as workflows move into larger manufacturing volumes.
Additional bioprocessing resources
Bioprocessing resources
For Research Use or Further Manufacturing. Not for use in diagnostic procedures.